Shares of FibroGen, Inc (NASDAQ:FGEN) have earned a consensus recommendation of “Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $66.60.

Several equities research analysts have recently weighed in on FGEN shares. Zacks Investment Research cut shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, May 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research report on Thursday, June 22nd. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research report on Monday, June 26th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $48.00 price target on shares of FibroGen in a research report on Monday, June 26th.

FibroGen (FGEN) opened at 44.05 on Tuesday. FibroGen has a 12-month low of $15.60 and a 12-month high of $51.70. The stock’s 50 day moving average is $35.25 and its 200 day moving average is $28.50. The stock’s market capitalization is $3.14 billion.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. The company had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities analysts predict that FibroGen will post ($1.82) earnings per share for the current fiscal year.

In related news, insider K Peony Yu sold 3,721 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $28.95, for a total transaction of $107,722.95. Following the completion of the sale, the insider now owns 221,507 shares of the company’s stock, valued at $6,412,627.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $28.50, for a total transaction of $57,000.00. Following the sale, the director now directly owns 34,000 shares of the company’s stock, valued at approximately $969,000. The disclosure for this sale can be found here. Insiders sold a total of 477,938 shares of company stock valued at $17,570,645 in the last ninety days. Corporate insiders own 14.90% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. purchased a new stake in FibroGen during the first quarter worth approximately $111,000. Quantbot Technologies LP purchased a new stake in FibroGen during the second quarter worth approximately $128,000. SG Americas Securities LLC boosted its stake in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Airain ltd purchased a new stake in FibroGen during the first quarter worth approximately $236,000. Finally, Amalgamated Bank purchased a new stake in FibroGen during the second quarter worth approximately $237,000. 43.03% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/15/fibrogen-inc-nasdaqfgen-given-consensus-recommendation-of-buy-by-analysts.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.